Conor Daly is a U.S.-born, professional racing driver who competes full-time while living with Type 1 Diabetes. Like many professional racing drivers, Daly started regularly competing in karting at the age of 10. Four years later, he found himself heading to the hospital having lost weight and possessing an insatiable thirst for water.
“I ended up not racing that day, but rather had tests run to learn what was going on with me,” Daly said. The answer came in the form of his Type 1 Diabetes diagnosis. “I knew that this was just another challenge life was presenting, and I wasn’t going to let it slow me down,” he said.
True to his conviction, less than a week later he was back to racing at the go-kart track and went on to take home the title at the 2006 World Karting Association Grand Nationals. Daly progressed to car racing in 2007, and has continued to thrive in the sport he loves. Over the past eight years, he has competed in over 100 NTT INDYCAR SERIES races, and has recently joined the NASCAR Xfinity Series.
Conor Daly is an Afrezza® user and a paid spokesperson for MannKind.
*Starts lowering blood sugar in ~12 minutes.
Once inhaled, Afrezza® passes quickly through your lungs and enters your bloodstream in less than 1 minute. The ultra rapid-acting insulin allows Afrezza® to start lowering blood sugar in about 12 minutes.
Afrezza® stops lowering blood glucose after 1.5 to 3 hours, depending on the dose.* This gives you the flexibility to take additional doses if needed, based on your blood glucose level after meals.
*For the 4-unit and 12-unit cartridges, respectively.
Afrezza®’s ultra rapid-action allows you to inhale your insulin right when food arrives, even unexpectedly, so you can be spontaneous but still in control, without the need for injections at mealtime.
Join Our List To Stay Updated With Helpful Information And Resources On Getting Started With Afrezza.
*MannKind engages third party service providers to perform certain services on our behalf. Pursuant to our Privacy Policy, we may share your information with one or more of our service providers in order to help assess whether Afrezza® (insulin human) Inhalation Powder is appropriate for you. MannKind and its service provider may contact you in a number of ways, including phone, text and email. Your consent to being contacted is not required to purchase MannKind products or services, nor does it obligate you to purchase MannKind products or services. You may contact MannKind at any time to obtain additional information or to opt-out of receiving telephone calls, by calling 818-661-5000.
US-AFR-2160
AFREZZA is a man-made insulin that is breathed-in through your lungs (inhaled) and is used to control high blood sugar in adults with diabetes mellitus.
What is the most important information I should know about AFREZZA? AFREZZA can cause serious side effects, including:
Sudden lung problems (bronchospasms). In a study, some AFREZZA-treated patients with asthma, whose asthma medication was temporarily withheld, experienced sudden lung problems. Do not use AFREZZA if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting AFREZZA, your healthcare provider will give you a breathing test to check how your lungs are working.
Do not use Afrezza® if you:
Before using Afrezza®, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements.
Before you start using Afrezza®, talk to your healthcare provider about low blood sugar and how to manage it.
While using Afrezza® do not:
Afrezza® may cause serious side effects that can lead to death, including:
See “What is the most important information I should know about Afrezza®?”
Treatment with TZDs and Afrezza® may need to be changed or stopped by your healthcare provider if you have new or worse heart failure.
Get emergency medical help if you have:
• Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.
The most common side effects of Afrezza® include:
These are not all the possible side effects of Afrezza®. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).
Please See Full Prescribing Information, including BOXED WARNING, Medication Guide and Instructions for Use for AFREZZA.
AFREZZA, the Afrezza logo, AFREZZAASSIST, AFREZZAASSIST and logo, MANNKIND, and BLUHALE VIS are registered trademarks of MannKind Corporation. © 2024 MannKind Corporation.
This site is intended for use by U.S. residents only.
Complete a quick medical questionnaire to help determine if Afrezza is right for you.
Schedule an appointment with a licensed healthcare provider.
If Afrezza is right for you, pick it up from your local pharmacy or have it delivered to your home.
You are now leaving Afrezza.com
By clicking “Yes” below, you acknowledge and agree that MannKind does not, in any way, endorse or recommend the qualifications of any physician associated with the third-party website, or the quality of medical care any of those physicians can provide. MannKind makes no guarantees that using the third-party website will result in your desired outcome. It is wholly and solely your responsibility to assess the qualifications of a potential physician. MannKind recommends that you meet and discuss the benefits and risks of all potential treatments with the potential physician. MANNKIND AND ITS RESPECTIVE AFFILIATES HEREBY DISCLAIM ANY LIABILITY ARISING FROM YOUR USE AND/OR RELIANCE ON THE INFORMATION CONTAINED ON THE THIRD-PARTY WEBSITE.
If you agree to the above, click “YES” to proceed to the third-party website. If you do not agree to the above, click “NO” to remain on Afrezza.com.